Avenue Therapeutics

General Information

We are a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain. Tramadol is a synthetic dual-acting opioid with a well-established efficacy and safety profile, and has been used throughout the world for more than 30 years, accumulating an abundance of available clinical data.

Employees: 3
Founded: 2015
Contact Information
Address 2 Gansevoort Street, 9th Floor,New York, NY 10014, US
Phone Number (781) 652-4500
Web Address http://www.avenuetx.com
View Prospectus: Avenue Therapeutics
Financial Information
Market Cap $53.0mil
Revenues $0 mil (last 12 months)
Net Income $-2.79 mil (last 12 months)
IPO Profile
Symbol ATXI
Exchange NASDAQ
Shares (millions): 5.5
Price range $6.00 - $6.00
Est. $ Volume $33.0 mil
Manager / Joint Managers Oppenheimer
CO-Managers National Securities Corp.
Expected To Trade: 6/27/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change